PFS
NRIX icon

Prospera Financial Services’s Nurix Therapeutics NRIX Stock Holding History

Prospera Financial Services’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-200
Closed -$3K – 1346
2022
Q2 		$3K Sell
200
-4,011
-95% -$45.5K ﹤0.01% 1519
2022
Q1 		$59K Buy
+4,211
New +$74.7K ﹤0.01% 1298

Other funds holding NRIX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Prospera Financial Services's NRIX Position: Q3 2022 in Review

Prospera Financial Services sold out of Nurix Therapeutics (NRIX) in Q3 2022, closing a stake of 200 shares — an estimated $3K sold.

Prospera Financial Services first reported a position in NRIX in Q1 2022 and held it in 2 quarters. The position peaked at $59K in Q1 2022. 118 funds tracked by Wall St. Rank hold NRIX as of Q3 2022.

  • Prospera Financial Services reported no remaining Nurix Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Prospera Financial Services sold 200 Nurix Therapeutics shares in Q3 2022, an estimated $3K.
  • Prospera Financial Services first reported a position in Nurix Therapeutics in Q1 2022 and held it in 2 quarters.
  • Prospera Financial Services's Nurix Therapeutics position peaked at $59K in Q1 2022.
  • 118 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2022.

Based on Prospera Financial Services's 13F filing for Q3 2022, filed 27 Oct 2022.